Search

Your search keyword '"Bartlett, Susan J."' showing total 23 results
Start Over Author "Bartlett, Susan J." Publisher wiley
23 results on '"Bartlett, Susan J."'

1. Predictors of Influenza Vaccination in Early Rheumatoid Arthritis 2017‐2021: Results From the Canadian Early Arthritis Cohort

Author

Ta, Viviane, primary, Schieir, Orit, additional, Valois, Marie‐France, additional, Colmegna, Ines, additional, Hitchon, Carol, additional, Bessette, Louis, additional, Hazlewood, Glen, additional, Thorne, Carter, additional, Pope, Janet, additional, Boire, Gilles, additional, Tin, Diane, additional, Keystone, Edward C., additional, Bykerk, Vivian P., additional, and Bartlett, Susan J., additional

Published
2022
Full Text
View/download PDF

2. Identifying Minimal and Meaningful Change in a Patient‐Reported Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives

Author

Bartlett, Susan J., primary, Gutierrez, Anna Kristina, additional, Andersen, Kathleen M., additional, Bykerk, Vivian P., additional, Curtis, Jeffrey R., additional, Haque, Uzma J., additional, Orbai, Ana‐Maria, additional, Jones, Michelle R., additional, and Bingham, Clifton O., additional

Published
2022
Full Text
View/download PDF

5. Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique

Author

Kelly, Ayano, primary, Tymms, Kathleen, additional, Wit, Maarten, additional, Bartlett, Susan J., additional, Cross, Marita, additional, Dawson, Therese, additional, De Vera, Mary, additional, Evans, Vicki, additional, Gill, Michael, additional, Hassett, Geraldine, additional, Lim, Irwin, additional, Manera, Karine, additional, Major, Gabor, additional, March, Lyn, additional, O’Neill, Sean, additional, Scholte-Voshaar, Marieke, additional, Sinnathurai, Premarani, additional, Sumpton, Daniel, additional, Teixeira‐Pinto, Armando, additional, Tugwell, Peter, additional, Bemt, Bart, additional, and Tong, Allison, additional

Published
2020
Full Text
View/download PDF

10. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis

Author

Harris, Michelle L., primary, Darrah, Erika, additional, Lam, Gordon K., additional, Bartlett, Susan J., additional, Giles, Jon T., additional, Grant, Audrey V., additional, Gao, Peisong, additional, Scott, William W., additional, El‐Gabalawy, Hani, additional, Casciola‐Rosen, Livia, additional, Barnes, Kathleen C., additional, Bathon, Joan M., additional, and Rosen, Antony, additional

Published
2008
Full Text
View/download PDF

22. Characterizing Nonarticular Pain at Early Rheumatoid Arthritis Diagnosis: Evolution Over the First Year of Treatment and Impact on Remission in a Prospective Real-World Early Rheumatoid Arthritis Cohort.

Author

Meng CF, Lee YC, Schieir O, Valois MF, Butler MA, Boire G, Hazlewood G, Allard-Chamard H, Hitchon C, Bindee K, Tin D, Thorne C, Bessette L, Pope J, Bartlett SJ, and Bykerk VP

Abstract

Objective: Our objective was to characterize nonarticular pain (NAP) at early rheumatoid arthritis (RA) diagnosis, the evolution over the first year of treatment, associations with active RA inflammation, and the impact on remission., Methods: This real-world, longitudinal multicenter cohort study observed participants with active early RA (symptoms <1 year and Clinical Disease Activity Index [CDAI] >2.8) enrolled between January 2017 and January 2022 who completed a body pain diagram over 1 year. Participants were grouped by prespecified definitions of NAP: (1) none, (2) regional, or (3) widespread. Rheumatologists performed joint counts. Descriptive statistics summarized the frequency and evolution of NAP patterns over 1 year. Chi-square tests compared the proportions of tender and/or swollen joints by the presence of pain in each NAP section. Multiadjusted generalized estimating equations regression models estimated associations of NAP patterns with remission outcomes., Results: Participants (N = 392) were 70% female, with a mean ± SD age of 56 ± 14 years and mean ± SD symptoms duration of 5.1 ± 2.7 months. More than half reported NAP at baseline, with most (73%) presenting with regional NAP. Common patterns of regional NAP were axial (40%) and pain in upper quadrants (17%). A total of 43% of those with regional NAP persisted or worsened over 1 year, whereas 73% of those with widespread NAP resolved or improved. Joint inflammation was more frequently reported in areas with NAP versus areas without NAP. Regional and widespread NAP were associated with lower odds of reaching CDAI remission (adjusted odds ratio 0.42, 95% confidence interval 0.26-0.70 and adjusted odds ratio 0.30, 95% confidence interval 0.12-0.74), respectively., Conclusion: Regional NAP is common and persistent in early RA and impacts remission. RA activity may contribute to NAP. More attention to NAP in RA care is warranted., (© 2024 The Author(s). Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)

Published
2024
Full Text
View/download PDF

23. Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort.

Author

Holdren M, Schieir O, Bartlett SJ, Bessette L, Boire G, Hazlewood G, Hitchon CA, Keystone E, Tin D, Thorne C, Bykerk VP, and Pope JE

Subjects
Adult, Aged, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid blood, Arthritis, Rheumatoid drug therapy, Blood Sedimentation, C-Reactive Protein metabolism, Canada, Cohort Studies, Female, Humans, Male, Middle Aged, Remission Induction, Severity of Illness Index, Arthritis, Rheumatoid physiopathology, Fatigue physiopathology
Abstract

Objective: To examine the relationship between disease activity and fatigue over time in early rheumatoid arthritis (RA)., Methods: Data were from patients with early RA (duration of symptoms ≤12 months) enrolled in the Canadian Early Arthritis Cohort (CATCH). Patients rated their fatigue over the past week using an 11-point numerical rating scale (NRS) for up to 5 years of follow-up. Fatigue severity was classified as low (≤2), moderate (>2 but <5), or high (≥5). Differences in fatigue ratings in patients who achieved a low disease state (Disease Activity Score in 28 joints [DAS28] <3.2) and those who did not within 3-months of cohort entry were compared., Results: Of 1,864 patients included, 88% met RA criteria, and 72% were women. The mean ± SD baseline DAS28 was 4.9 ± 1.5. Nineteen percent of the patients reported moderate baseline fatigue, and 59% reported severe baseline fatigue. Fatigue was correlated with pain and patient global ratings (r = 0.56-0.67, P < 0.001), and was weakly correlated with DAS28, tender joint count, swollen joint count, physician global assessment of disease activity, erythrocyte sedimentation rate, and C-reactive protein level. Patients who reported low fatigue by 3 months had significantly lower fatigue throughout follow-up compared to those who had moderate or high fatigue at 3 months (P < 0.001). Patients who achieved a DAS28 <3.2 within 3 months had significantly lower fatigue ratings (mean ± SD 2.7 ± 2.6) than those with a DAS28 >3.2 (4.6 ± 3.0) (P < 0.001), with improvements in fatigue that persisted through 5 years of follow-up. Maximal improvements in fatigue lagged behind remission by 6 months., Conclusion: Fatigue is common in early RA, and improvements may occur after remission. Early treatment response within 3-months was associated with short-term and long-term benefits in fatigue over time., (© 2020, American College of Rheumatology.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results